| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and nine months ended August 31, 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
|
For the three months ended August 31, |
|
|
|
2025 |
|
|
2024 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
7,820,877 |
|
|
$ |
7,945,470 |
|
PrepaCyte CB |
|
|
436 |
|
|
|
636 |
|
Public cord blood banking |
|
|
4,119 |
|
|
|
120,609 |
|
Total net revenue |
|
$ |
7,825,432 |
|
|
$ |
8,066,715 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,666,952 |
|
|
$ |
1,859,090 |
|
PrepaCyte CB |
|
|
2,295 |
|
|
|
1,220 |
|
Public cord blood banking |
|
|
132,172 |
|
|
|
265,536 |
|
Total cost of sales |
|
$ |
1,801,419 |
|
|
$ |
2,125,846 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
2,032,929 |
|
|
$ |
1,542,346 |
|
PrepaCyte CB |
|
|
(4,340 |
) |
|
|
(7,529 |
) |
Public cord blood banking |
|
|
(128,053 |
) |
|
|
(144,927 |
) |
Total operating profit |
|
$ |
1,900,536 |
|
|
$ |
1,389,890 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
183,212 |
|
|
$ |
187,614 |
|
PrepaCyte CB |
|
|
2,481 |
|
|
|
6,945 |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total depreciation and amortization |
|
$ |
185,693 |
|
|
$ |
194,559 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
538,219 |
|
|
$ |
533,464 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
538,219 |
|
|
$ |
533,464 |
|
|
|
|
|
|
|
|
|
|
For the nine months ended August 31, |
|
|
|
2025 |
|
|
2024 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
23,558,484 |
|
|
$ |
23,716,492 |
|
PrepaCyte CB |
|
|
35,785 |
|
|
|
39,470 |
|
Public cord blood banking |
|
|
128,886 |
|
|
|
205,799 |
|
Total net revenue |
|
$ |
23,723,155 |
|
|
$ |
23,961,761 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
5,020,695 |
|
|
$ |
5,574,109 |
|
PrepaCyte CB |
|
|
13,537 |
|
|
|
37,083 |
|
Public cord blood banking |
|
|
608,314 |
|
|
|
699,872 |
|
Total cost of sales |
|
$ |
5,642,546 |
|
|
$ |
6,311,064 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
4,922,731 |
|
|
$ |
4,115,571 |
|
PrepaCyte CB |
|
|
5,878 |
|
|
|
(18,447 |
) |
Public cord blood banking |
|
|
(479,428 |
) |
|
|
(494,493 |
) |
Total operating profit |
|
$ |
4,449,181 |
|
|
$ |
3,602,631 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
551,278 |
|
|
$ |
266,289 |
|
PrepaCyte CB |
|
|
16,370 |
|
|
|
20,834 |
|
Public cord blood banking |
|
|
— |
|
|
|
420 |
|
Total depreciation and amortization |
|
$ |
567,648 |
|
|
$ |
287,543 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,584,307 |
|
|
$ |
1,119,196 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
1,584,307 |
|
|
$ |
1,119,196 |
|
The following table shows the assets by segment as of August 31, 2025 and November 30, 2024:
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
As of |
|
|
|
August 31, 2025 |
|
|
November 30, 2024 |
|
Assets: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell
service |
|
$ |
57,911,818 |
|
|
$ |
59,259,451 |
|
PrepaCyte CB |
|
|
92,684 |
|
|
|
138,169 |
|
Public cord blood banking |
|
|
5,164,627 |
|
|
|
5,280,013 |
|
Total assets |
|
$ |
63,169,129 |
|
|
$ |
64,677,633 |
|
|